Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ALLO 
Allogene Therapeutics Inc (ALLO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ALLO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -21.45% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 336.76M USD | Price to earnings Ratio - | 1Y Target Price 8.75 |
Price to earnings Ratio - | 1Y Target Price 8.75 | ||
Volume (30-day avg) 4473024 | Beta 1.02 | 52 Weeks Range 1.30 - 4.30 | Updated Date 03/31/2025 |
52 Weeks Range 1.30 - 4.30 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-12 | When Before Market | Estimate -0.3234 | Actual -0.28 |
Profitability
Profit Margin - | Operating Margin (TTM) -1170372.8% |
Management Effectiveness
Return on Assets (TTM) -27.01% | Return on Equity (TTM) -55.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 135040343 | Price to Sales(TTM) 15307.31 |
Enterprise Value 135040343 | Price to Sales(TTM) 15307.31 | ||
Enterprise Value to Revenue 6138.2 | Enterprise Value to EBITDA -1.04 | Shares Outstanding 217264992 | Shares Floating 156267663 |
Shares Outstanding 217264992 | Shares Floating 156267663 | ||
Percent Insiders 17.73 | Percent Institutions 77.84 |
Analyst Ratings
Rating 4.18 | Target Price 9.23 | Buy 4 | Strong Buy 8 |
Buy 4 | Strong Buy 8 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Allogene Therapeutics Inc
Company Overview
History and Background
Allogene Therapeutics Inc. was founded in 2018 as a spin-off from Pfizer and is headquartered in South San Francisco, California. The company focuses on developing allogeneic CAR T-cell therapies for cancer. A significant milestone was the initiation of clinical trials for its lead product candidate, ALLO-501. The company has evolved from initial research and development to clinical-stage development and faces regulatory hurdles.
Core Business Areas
- Allogeneic CAR T-cell Therapy Development: Development of off-the-shelf CAR T-cell therapies for hematologic malignancies and solid tumors.
Leadership and Structure
David Chang, M.D., Ph.D., is the President and CEO. The company has a typical corporate structure with a board of directors and various executive leadership positions overseeing research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- Allo-501: Allogene's lead product candidate targeting CD19 for hematologic malignancies. Currently in clinical trials. Market share is currently 0%, as it is not yet approved for commercial use. Competitors include companies developing autologous CAR T-cell therapies such as Novartis (Kymriah), Gilead (Yescarta), and Bristol Myers Squibb (Breyanzi).
- Allo-715: A BCMA-targeting allogeneic CAR T-cell therapy for multiple myeloma. Currently in clinical trials. Market share is currently 0%, as it is not yet approved for commercial use. Competitors include companies developing BCMA-targeting therapies such as Bristol Myers Squibb (Abecma), and Johnson & Johnson (Carvykti).
Market Dynamics
Industry Overview
The industry is rapidly growing with significant innovation in cell and gene therapy. The CAR T-cell therapy market is competitive, driven by advancements in immuno-oncology. There's increasing demand for off-the-shelf therapies to overcome limitations of autologous CAR T-cell therapies.
Positioning
Allogene aims to be a leader in allogeneic CAR T-cell therapy by developing readily available, cost-effective treatments. Its competitive advantage lies in its allogeneic approach, which eliminates the need for patient-specific cell manufacturing and reduces treatment time.
Total Addressable Market (TAM)
The CAR T-cell therapy market is projected to reach billions of dollars. Allogene aims to capture a significant portion of this market by offering an allogeneic option, estimated at $4 Billion by 2030. Allogene is positioned to capitalize on the increasing demand for readily available cell therapies.
Upturn SWOT Analysis
Strengths
- Allogeneic CAR T-cell platform
- Experienced leadership team
- Strong intellectual property portfolio
- Potential for off-the-shelf therapies
Weaknesses
- Clinical trial risks
- Regulatory hurdles
- Manufacturing scalability challenges
- Dependence on clinical trial success
Opportunities
- Expanding into new cancer indications
- Partnerships and collaborations
- Advancements in gene editing technology
- Increased adoption of cell therapies
Threats
- Competition from autologous CAR T-cell therapies
- Adverse events in clinical trials
- Pricing and reimbursement pressures
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- GILD
- BMY
- NVS
- JNJ
Competitive Landscape
Allogene's allogeneic approach offers potential advantages over autologous therapies in terms of cost and accessibility. However, it faces competition from established autologous CAR T-cell therapies and other emerging cell therapy technologies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by clinical trial progress. Stock price fluctuates based on clinical data releases.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and market adoption of its allogeneic CAR T-cell therapies. Analyst estimates vary, but generally project revenue growth upon commercialization of lead candidates.
Recent Initiatives: Initiation and progression of clinical trials for Allo-501 and Allo-715, expansion of manufacturing capabilities, and exploration of new therapeutic targets.
Summary
Allogene Therapeutics is a clinical-stage biotechnology company focusing on allogeneic CAR T-cell therapies, offering potential advantages over current autologous methods. The company's success is contingent upon favorable clinical trial outcomes and regulatory approvals for its lead candidates. Although the allogeneic approach has benefits, it faces stiff competition and regulatory challenges. Allogene needs to focus on successful trial outcomes and scalable manufacturing.
Similar Companies
- GILD
- BMY
- NVS
- JNJ
Sources and Disclaimers
Data Sources:
- Allogene Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance may change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allogene Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-10-11 | Co-Founder, President, CEO & Director Dr. David D. Chang M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 226 | Website https://www.allogene.com |
Full time employees 226 | Website https://www.allogene.com | ||
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 2 clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it provides clinical-stage product, such as LLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors ; Claudin 18.2 for the treatment of gastric and pancreatic cancer; FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.